Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIS954 in Antineutrophil Cytoplasmic Antibody-associated Vasculitis
NCT07904806Phase 2Not yet recruiting
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Dec 2026
- Primary completion
- Nov 2029
01
Overview
Phase 2, randomised, double-blind trial of VIS-954 in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) (3 arms), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoints: Proportion of Participants in Remission at Week 24 and Incidence of Treatment-Emergent Adverse Events at Week 24. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
VIS-954
03
Conditions
anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV)
Beyond the preview
Go deeper on NCT07904806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07904806.